5-FU resistant colorectal cancer cells possess improved invasiveness and βIII-tubulin expression

Akalovich S.1, Portyanko A.2, Pundik A.1, Mezheyeuski A.3, Doroshenko T.*4

Summary. Background: Elevated βIII-tubulin levels are associated with resistance to a broad spectrum of drugs in different carcinomas and with poor prognosis of various epithelial cancers. 5-Fluorouracil (5-FU) is a widely used standard drug in chemotherapeutic regimens for colorectal cancer treatment, although the resistance to 5-FU is a major obstacle to successful therapy. Aim: The aim of the study was to compare the invasive and adhesion properties and the expression levels of βIII-tubulin in a 5-fluorouracil (5-FU)-resistant colorectal cancer (CRC) cell line HCT116 and parental cells. Materials and Methods: The 5-FU-resistant cell line was established by continuous stepwise selection with increasing concentrations of 5-FU. Cell viability and properties were evaluated using MTT, adhesion and Transwell invasion assays, respectively. The expression of βIII-tubulin was revealed by immunoblot and immunofluorescence. Results: The derivative line is 25-fold more resistant to 5-FU and characterized by altered cell morphology. Twice as many cells of the 5-FU-resistant line fail to adhere as compared to the parental cell line. 5-FU-resistant cells are characterized by enhanced invasiveness, accompanied with the increased βIII-tubulin expression. In addition, we found that loss of βIII-tubulin expression was correlated with loss of 5-FU resistance. Conclusion: Our results indicate that even though 5-FU does not target microtubules, there appears to be a correlation between βIII-tubulin expression and resistance to 5-FU that is particularly important with regard to invasiveness. These findings indicate a possible contribution of βIII-tubulin to 5-FU resistance in vivo.

DOI: 10.32471/exp-oncology.2312-8852.vol-43-no-2.16314

Submitted: October 27, 2020.
*Correspondence: E-mail: tatmdoroshenko@gmail.com
Abbreviations used: 5-FU — 5-fluorouracil; CRC — colorectal cancer.

Colorectal cancer (CRC) is the fourth most common cancer-related cause of death in the world [1]. Failure of therapy is due to metastasis and chemoresistance of cancer cells, for instance, 5-year survival for a CRC patient with unresectable metastasis to distant organs treated with palliative chemotherapy is 2.2% [2]. 5-fluorouracil (5-FU) is a widely used standard drug in chemotherapeutic regimens for CRC treatment, although the resistance to 5-FU is a major obstacle to successful therapy [3]. Therefore, understanding the complex events underlying the development of resistance is essential. It was shown that 5-FU-resistant CRC cells were characterized by reduced apoptosis and a more aggressive growth phenotype, consistent with the observed up-regulation of apoptosis inhibitory genes, positive growth-regulatory genes, and metastasis genes and down-regulation of apoptosis-promoting genes [4–6]. For different epithelial cancer cell lines the connection between chemoresistance formation and more invasive phenotype was shown in vitro [7–10], with very limited data concerning the mechanism of such interrelation.

Tubulins form microtubules, which modulate fundamental cellular processes, such as cell division, movement, maintenance of cellular morphology, intracellular transport and active transport of cellular components throughout the cytoplasm, cell stress responses and others. Changes in microtubule stability and the expression of different tubulin isotypes as well as altered post-translational modifications have been reported for a range of cancers and have been correlated with poor prognosis and chemotherapy resistance [11]. βIII-tubulin is the most comprehensively examined isotype across a variety of cancers [12–15].

The elevated levels of βIII-tubulin are associated with poor prognosis of different epithelial cancers [11, 12, 15]. In addition to promoting resistance to tubulin-targeted agents, βIII-tubulin influences sensitivity to non-tubulin-targeted agents [12, 15]. The clinical observations of patients with solid tumors are supported by numerous in vitro studies where altered βIII-tubulin expression confers resistance to a broad spectrum of drug classes [11, 16–18]. However, the underlying mechanisms of the involvement of βIII-tubulin in inducing resistance to anti-tumor drugs have yet to be explained and are likely to be very complex.

The aim of this study was to characterize the changes in invasive and adhesion properties and expression of βIII-tubulin of the 5-FU-resistant CRC cell line HCT116 in comparison with the parental cell line. In this study, we establish a 5-FU resistant cell line HCT116-5-FU using stepwise increasing drug concentrations and short exposures. We confirmed its association with decreased adhesiveness and increased invasive phenotype, accompanied with the increased βIII-tubulin expression.


Cell culture. HCT116 human CRC line (ATCC CCL247) was grown in RPMI-1640 medium (Lonza, Switzerland) supplemented with 25 mM HEPES, 2 mM L-glutamine, 100 U/mL penicillin and 100 μg/mL streptomycin and 5–10% fetal bovine serum (FBS) (HyClone™, Fisher Scientific Co. LLC, USA) (complete media) in a humidified atmosphere with 5% CO2 at 37 ˚C.

To obtain the resistant cell line, the exponentially growing HCT116 cells for 48 h were treated with 5-FU (Merck KGaA, Germany) in complete culture medium followed by recovery drug-free periods until the cells achieved exponential growth, using 5-FU concentrations ranged from 0.04–0.80 mM. Drug treatment continued until cell line demonstrated stable resistance to 5-FU (about 10 months) as assessed by MTT assay. The parental HCT116 cells were also serially passaged as an untreated control along with the resistant derivatives. For experiments with the loss of resistance, cells were incubated in growth medium without 5-FU during 2 months and controlled for 5-FU resistance by MTT assay and for the βIII-tubulin content by Western blotting.

MTT assay. HCT116 cells or 5-FU-resistant derivate (5 × 103/well) were plated in 96-well culture plates and incubated overnight. Cells were treated with indicated concentrations of 5-FU for 48 h. The number of viable cells was determined by MTT assay using MTT reagent (Carl Roth, Germany) as described [19]. The percent viability was calculated from three wells as

346346346634 5 FU resistant colorectal cancer cells possess improved invasiveness and β<sub>III</sub> tubulin expression

The drug concentration that resulted in a 50% cell growth inhibition (IC50) was determined graphically using cell survival curves in which the percentages of survived cells were plotted as a function of 5-FU concentration.

Adhesion assay. Twenty-four well plates were coated with bovine collagen type I (Gibco, Thermo Fisher Scientific Inc, USA) at a concentration of 50 μg/ml at room temperature for 2 h. Cells (2 • 105 per well) in complete media were allowed to attach for 30 min at 37 ˚C in a humidified atmosphere with 5% CO2. Non-attached cells from each well were counted manually under a microscope and the cell adhesion rate (%) was calculated according to the formula:

457568568568 5 FU resistant colorectal cancer cells possess improved invasiveness and β<sub>III</sub> tubulin expression


The experiments were repeated five times in triplicates.

Invasive assay. Cell invasion was performed by the modified Boyden chamber method in 24-well plates with culture inserts with 8 μm pore size (Costar Corning, USA), coated with bovine collagen type I (Gibco, Thermo Fisher Scientific Inc, USA) or matrigel (Becton Dickinson and Company, USA) according to the manufacturer’s recommendations. Cells (5 • 104 cells/ml) were resuspended in RPMI-1640. The upper chamber was loaded with 100 µl of cell suspension and the lower chamber was loaded with 600 µl of RPMI-1640 with 10% FBS. After incubation for 24 h at 37 ˚C in 5% CO2, cells that penetrated to the lower chamber were fixed and stained with 4% paraformaldehyde and 0.2% crystal violet. Cells were counted under a microscope; five microscopic fields were randomly selected for cell counting. Each assay was performed in triplicate.

Western blotting. Proteins were extracted from the cells by lysis in RIPA buffer in the presence of protease inhibitors. The lysates were centrifuged (15 min at 14,800 g at 4 ˚C) and proteins were denatured by boiling for 5 min in loading buffer, separated by electrophoresis using 12.5% SDS-PAGE and blotted onto nitrocellulose membrane (Whatman Protran nitrocellulose membranes, Sigma-Aldrich Co. LLC, Germany). The membrane was blocked with blocking buffer (2% bovine serum albumin (BSA) in phosphate buffer saline (PBS)-Tween 1%) for 2 h and incubated overnight at 4 ˚C with the anti-human βIII-tubulin antibody 5G8 (Thermo Fisher Scientific Inc, USA) at 1:1000 or anti-human β-actin antibody at 1:1000 (Abcam, UK) as loading control. Anti-mouse immunoglobulin G, poly-horseradish peroxidase-conjugated antibody (EnVision, DAKO, Agilent Technologies, Inc., USA) was used as a secondary antibody and an immunoblott was developed with enhanced chemoluminescent (ECL) substrate (clarity Western ECL substrate, BioRad, Ireland, UK) and visualized using a Kodak Image Station 2000R and the ImageJ 1.47v (NIH, USA) software.

Immunofluorescence microscopy. Cells were grown on glass cover slips for about 70% confluent monolayer in complete RPMI-1640 medium. They were fixed for 10 min with ice-cold methanol and permeabilized with ice-cold acetone for 2 min at –20 ˚C. Cover slips were blocked for 30 min in PBS containing 2% BSA, and incubated with the anti-human βIII-tubulin mouse antibody 5G8 at 1:1000 overnight at 4 ˚C in a humid chamber. After incubation with Alexa Fluor 546-conjugated secondary antibody (Life Technologies, USA) for 2 h, cells were stained with DAPI for nuclear staining, mounted with ProLong Gold AntifadeMountant (Life Technologies, USA) and then visualized by a fluorescence microscope Leica DM5000В.

Statistical analysis. Data are provided as means ± SEM, or means ± SD, n represents the number of independent experiments. Levels of statistical significance were evaluated by using non-parametric Mann-Whitney test or Wilcoxon matched pairs test. Differences were considered statistically significant when p-values were less than 0.05.


We generated 5-FU-resistant cell lines from parental HCT116 cells by serial passage of HCT116 cells with repeated exposure to increasing 5-FU concentrations. These cells were designated as HCT116-5-FU. A MTT assay was performed to compare the viability of the 5-FU-resistant HCT116 and parental HCT116 cells. The IC50 values for the parental and derivative cells were determined as 0.012 and 0.3 mM, respectively (Fig. 1, a). These data indicate that the derivative line was 25-fold more resistant to 5-FU than was the parental HCT116 cell line.

The 5-FU-resistant cells were morpho­logically distinct from their parental cell line HCT116 (Fig. 1, b). Light microscopic analysis of the cell phenotype confirmed that the parental HCT116 cells were uniform in shape and grew with tight cell–cell junctions in monolayer culture. However, HCT116-5-FU cells appeared to have spindle-cell morphology with increased formation of pseudopodia and enlarged intercellular separation signifying loss of intercellular adhesion (Fig. 1, b).

 5 FU resistant colorectal cancer cells possess improved invasiveness and β<sub>III</sub> tubulin expression  5 FU resistant colorectal cancer cells possess improved invasiveness and β<sub>III</sub> tubulin expression
Fig. 1. HCT116-5-FU cells are resistant to 5-FU-induced cytotoxicity and have morphological changes in comparison with parental cell line HCT116: a — cells were treated with increasing concentrations of 5-FU (up to 1.5 mM) for 48 h, and cell viability was assessed by MTT and reported as percentage viability. Results are expressed as mean ± SD of triplicate. Similar results were obtained in three independent experiments; b — Acquisition of 5-FU resistance induces changes in cell morphology in HCT116-5-FU cells. Cells were examined using phase contrast microscopy (original magnification, × 200). The left panel shows the parental HCT116 cells and right panel — the HCT116-5-FU cells

To determine if the acquisition of 5-FU resistance induces changes in the adhesive ability and invasive potential of the cells, we compared HCT116 and HCT116-5-FU cells in adhesive and ECM (extracellular matrices) gel-coated Transwell invasive assays.

We found that HCT116-5-FU cells have a decreased capacity for attachment to collagen-treated plastic (n = 5, p = 0.043) (Fig. 2, a) and displayed enhanced invasiveness to a collagen- or matrigel-treated 8.0 µm pore size membrane in comparison with parental cells (n = 3; p = 0.001 and p = 0.03, respectively) (Fig. 2, b).

 5 FU resistant colorectal cancer cells possess improved invasiveness and β<sub>III</sub> tubulin expression
Fig. 2. HCT116-5-FU cells have altered adhesive and invasive capacity: a — quantitative analysis of cell adhesion to collagen-treated plastic. The percentage of non-attached cell after 30 min of incubation is presented as mean and SEM (error bars) for n = 5; b — quantitative analysis of cells invading through collagen or matrigel-coated Transwell chambers. Data are presented as mean and SEM (error bars) for n = 3. *p < 0.05; **p < 0.001

Previously we showed a preferential localization of βIII-tubulin in the invading epithelium in CRC specimens [20]. According to the current understanding, βIII-tubulin may represent a biomarker of the cancer aggressiveness, the response to therapy and poor outcome in a broad spectrum of epithelium cancers, regardless of chemotherapy composition [21–28]. We studied the expression of βIII-tubulin in parental and 5-FU resistant cell lines. The Western blot analysis demonstrated that HCT116-5-FU cells expressed increased βIII-tubulin protein relative to the parental HCT116 cells (Fig. 3, a). The immunofluorescence assay also revealed that resistant cells had increased contents of βIII-tubulin expression compared to HCT116 (Fig. 3, b).

 5 FU resistant colorectal cancer cells possess improved invasiveness and β<sub>III</sub> tubulin expression
 5 FU resistant colorectal cancer cells possess improved invasiveness and β<sub>III</sub> tubulin expression
Fig. 3. HCT116-5-FU cells have increased expression of bIII-tubulin: a — Immunoblotting of βIII-tubulin protein expression by HCT116-5-FU and HCT116. Expression was normalized to β-actin. Results are presented as mean and SEM for n = 3, p < 0.05, compared with parental HCT116 cells (left) and as representative immunoblot of HCT116-5-FU and HCT116 cells (right); b — Immunofluorescence staining for the expression and cellular localization of βIII-tubulin (red). DAPI was used as a nuclear stain (blue). Original magnification, × 400

It is important to note that the level of βIII-tubulin expression by HCT116-5-FU cells decreased during the long period of culturing in the absence of 5-FU. At the same time, resistance to 5-FU was lost as confirmed by the MTT-test (Fig. 4).

 5 FU resistant colorectal cancer cells possess improved invasiveness and β<sub>III</sub> tubulin expression
Fig. 4. Immunoblotting of bIII-tubulin protein expression by HCT116-5-FU depending on 5-FU resistance, presented as ratio IC50 to 5-FU of resistant cells (HCT116-5-FU) to parental cell HCT116. HCT116-5-FU cells were cultured without drug for 0 day (resistance indicated as 25x), for 1 month (indicated as 20x) and for 2 months (indicated as 12x). HCT116 cells were also serially passaged as an untreated control along with the resistant derivatives. Expression was normalized to β-actin. Results are shown as mean ± SD of triplicate. Similar results were obtained using two independent cell culturing


5-FU is widely used for treatment of digestive system cancers and it is a first-line chemotherapeutic agent for CRC treatment, preferentially used in combination with other chemotherapeutic drugs such as irinotecan [29]. The detailed mechanism of the clinical response to 5-FU chemo­therapy is still unclear as cancer cells gain resistance to 5-FU over time, which is a serious problem for 5-FU-based chemo­therapy. Although several key biochemical pathways involved in 5-FU resistance have been investigated [30, 31], its definitive mechanism in CRC is still unclear. A better understanding of how residual tumor cells survive after chemotherapy and what molecular alterations cause or correlate with resistance could ultimately provide new, more effective therapeutic strategies for patients diagnosed with CRC. In this study, we obtained a 5-FU-resistant CRC cell line HCT116 and investigated the changes in the cellular behaviors and associated expression of βIII-tubulin marker in comparison with parental cells.

We found that cells acquiring resistance to 5-FU have undergone certain morphological changes — formation of spindle-shaped cells, pseudopodia and loss of cell-cell adhesion, together with enhanced invasive and decreased adhesive ability. Such changes at the cellular level in vitro suggests a cascade of events at the tumor level in vivo including loss of adhesion and tight junctions, dissociation of epithelial layer into separate cells and local invasion, which is the first and key step in the metastatic process [32].

In agreement with our findings, changes in cell morphology and cell invasiveness were also reported for acquired resistance to 5-FU in other cancer cells, namely, breast [8] and squamous cell carcinoma [9]. Moreover, resistance to drugs of different mechanisms of action in a broad spectrum of cancer cell lines leads to the formation of similar changes in cells [8–10, 33] indicating that chemotherapy induces the same survival mechanisms in different epithelial cancer, contributing to the formation of tumor cells of high-grade malignancy.

In the present report, we showed that these changes­ in cellular behavior of 5-FU-resistant CRC cells were accompanied by elevated expression of βIII-tubulin. Microtubule alterations are thought to influence cellular responses to chemotherapeutic and micro-environmental stressors, thereby contributing to a broad-spectrum chemotherapy resistance. In clinical studies, the correlation between poor response to treatment and high βIII-tubulin expression, for example, in uterine serous carcinoma [21] and ovarian cancer in response to taxane/platinum [22, 23], gastric [24] and breast cancer in response to taxane [25, 26], non-small cell lung cancer in response to tubulin-binding agents [27, 28] was shown.

As far as we are aware, there is no data supporting a predictive value for βIII-tubulin in CRC. However, here we have shown that the significantly increased expression of βIII-tubulin in 5-FU-resistant CRC HCT116 cells is associated with increased invasiveness, suggesting­ that such a correlation may be relevant to CRC patients. To our knowledge, this is the first study reporting the overexpression of βIII-tubulin in CRC cells with acquired resistance to 5-FU characterized by enhanced invasiveness.

Considering all evidence to date regarding the properties of βIII-tubulin and its role in cancer cells, it is possible to speculate about how βIII-tubulin may work in colon cancer. It should be noted that each of these features has been strongly conserved in the evolution of vertebrate βIII-tubulin for at least half a billion years, suggesting that they are functionally highly significant.

Firstly, βIII-tubulin has Ser239 instead of Cys239 present in the other tubulin βI-, βII-, βIVa- and βIVb-isotypes. The sulfhydryl of Cys239 is extremely sensitive to oxidation, which inhibits microtubule assembly [34, 35]. The replacement of this sulfhydryl group in βIII-tubulin allows it to function in cells with high levels of free radicals and reactive oxygen species such as aggressive metastatic cancers [36–40], since it was shown that reactive oxygen species inhibit microtubule assembly [41–43].

Secondly, the replacement of Ser124 in the βI-, βII-, βIVa- and βIVb-tubulin isotypes with Cys124 in βIII-tubulin and its very close position with respect to Cys127 and Cys129, present in all vertebrate β-tubulin isotypes and, in fact, in almost all of the eukaryotic β-tubulins allow forming a sulfhydryl cluster that could perhaps help to scavenge free radicals. This role has been proposed and discussed but never directly demonstrated [12, 44]. βIII-tubulin could play such a role in CRC as well as in other cancers. It should be noted that such a role does not necessitate that βIII-tubulin be part of a microtubule.

Thirdly, βIII-tubulin has an unusual C-terminal region — residues 431–450, where βIII-tubulin has a serine that can be phosphorylated [45] and ends with a basic residue. Recent discoveries have shown that βIII-tubulin plays a role in signaling in pro-survival pathways [13, 25, 30, 46–50] and this is consistent with its unusual and highly conserved structure. The presence of a highly negatively charged C-terminal domain could easily protect the βIII-tubulin molecule from both microtubule and free-floating form and interact with signaling molecules.

In discussing the functional significance of the C-termini of the tubulin as a possible participant of signaling pathway, the most obvious prediction is that the unique C-terminus of βIII-tubulin could be part of a unique signaling pathway. The potentially important signaling role of βIII-tubulin is confirmed by the fact that βIII-tubulin undergoes both transcriptional and post-transcriptional regulation [30, 51]. In the recent paper by Parker et al. [52], the role of βIII-tubulin as part of a signaling pathway was demonstrated, with an emphasis on its role in regulating glucose metabolism in non-small cell lung cancer. It is probable that βIII-tubulin is in a signaling pathway with MDR, as Li et al. [16] have suggested. It is certainly possible that βIII-tubulin has a signaling role in CRC, although what that role could be is not clear.

And finally, the fourth distinctive feature of βIII-tubulin is that it forms much more dynamic microtubules than is the case for microtubules formed from either βII-tubulin or βIV-tubulin [53]. The ability to form very dynamic microtubules would be important in cells that are changing their shape, dividing rapidly and migrating, all of which would apply to metastatic cells. These observations can explain the overexpression of βIII-tubulin in CRC. Moreover, the elevation of βIII-tubulin in embryonic tissues [54, 55] or in stem cells even in those that are not neuronal [56, 57] can be explained by the necessity of rapid growth and morphological changes.

All four of these issues contribute to the complexity of cancer therapy and to the contradictory effects of βIII-tubulin on resistance to anti-tumor drugs. Taking into account all of the above, we should mention that there is no data that 5-FU interacts directly with microtubules. Nevertheless, each model described above could conceivably explain the correlation that we have observed. We hope that further experiments will be able to clarify the hypotheses presented here and lead to improved chemotherapeutic regiments in CRC.

We showed for the first time the up-regulation of βIII-tubulin, the cytoskeleton microtubular component, in 5-FU resistant cancer cell line that demonstrated increased invasive potential and altered cell morphology. Our data being in agreement with broad clinical studies on predictive value of βIII-tubulin revealed its association with chemotherapy resistance both to tubulin-targeted and non-tubulin-targeted agents. Our findings of βIII-tubulin accumulation in cancer cells during resistance formation suggest that βIII-tubulin may serve not only as a marker of poor response to chemotherapy, but also as a potential target for the prevention of the chemoresistance formation.


This study was funded by the Ministry of Health of Republic of Belarus (grant № 1.2.42) and International Scientific and Technology Center (ISTC №B-1636).


The authors declare that they have no conflict of interest regarding the publication of this paper.


1. Cancer Today website: http://gco.iarc.fr.
2. Engstrand J, Nilsson H, Strömberg C, et al. Colorectal cancer liver metastases — a population-based study on incidence, management and survival. BMC Cancer 2018; 18: 78.
3. Iqbal S, Stoehlniacher J, Lenz H. Tailored chemotherapy for colorectal cancer: a new approach to therapy. Cancer Invest 2004; 22: 762–73.
4. de Angelis P, Fjell B, Kravik K, et al. Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil. Int J Oncol 2004; 24: 1279–88.
5. De Angelis P, Svendsrud D, Kravik K, et al. Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery. Mol Cancer 2006; 5: 20.
6. De Angelis P, Kravik K, Tunheim S, et al. Comparison of gene expression in HCT116 treatment derivatives generated by two different 5-fluorouracil exposure protocols. Mol Cancer 2004; 3: 11.
7. Shen W, Pang H, Liu J, et al. Epithelial-mesenchymal transition contributes to docetaxel resistance in human non-small cell lung cancer. Oncol Res 2014; 22: 47–55.
8. Zhang W, Feng M, Zheng G, et al. Chemoresistance to 5-fluorouracil induces epithelial-mesenchymal transition via up-regulation of Snail in MCF7 human breast cancer cells. Biochem Biophys Res Commun 2012; 417: 679–85.
9. Harada K, Ferdous T, Ueyama Y. Establishment of 5-fluorouracil-resistant oral squamous cell carcinoma cell lines with epithelial to mesenchymal transition changes. Int J Oncol 2014; 44: 1302–8.
10. Shen W, Pang H, Liu J, et al. Epithelial-mesenchymal transition contributes to docetaxel resistance in human non-small cell lung cancer. Oncol Res 2014; 22: 47–55.
11. Cirillo L, Gotta M, Meraldi P. The elephant in the room: The role of microtubules in cancer. Adv Exp Med Biol 2017; 1002: 93–124.
12. Parker A, Kavallaris M, McCarroll J. Microtubules and their role in cellular stress in cancer. Front Oncol 2014; 4: 153.
13. Mariani M, Karki R, Spennato M, et al. Class III β-tubulin in normal and cancer tissues. Gene 2015; 563: 109–14.
14. Katsetos C, Herman M, Mörk S. Class III β-tubulin in human development and cancer. Cell Motil Cytoskeleton 2003; 55: 77–96.
15. Karki R, Mariani M, Andreoli M, et al. βIII-Tubulin: biomarker of taxane resistance or drug target? Expert Opin Ther Targets 2013; 17: 461–72.
16. Li W, Zhai B, Zhi H, et al. Association of ABCB1, β tubulin I, and III with multidrug resistance of MCF7/DOC subline from breast cancer cell line MCF7. Tumour Biol 2014; 35: 8883–91.
17. Gan P, McCarroll J, Byrne F, et al. Specific β-tubulin isotypes can functionally enhance or diminish epothilone B sensitivity in non-small cell lung cancer cells. PLoS One 2011; 6: e21717.
18. English D, Roque D, Santin A. Class III b-tubulin overexpression in gynecologic tumors: implications for the choice of microtubule targeted agents? Expert Rev Anticancer Ther 2013; 13: 63–74.
19. Longley D, Wilson T, McEwan M, et al. c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 2006; 25: 838–48.
20. Portyanko A, Kovalev P, Gorgun J, et al. βIII-tubulin at the invasive margin of colorectal cancer: possible link to invasion. Virchows Arch 2009; 454: 541–8.
21. Roque D, Bellone S, English D, et al. Tubulin- beta-III overexpression by uterine serous carcinomas is a marker for poor over- all survival after platinum/taxane chemotherapy and sensitivity to epothilones. Cancer 2013; 119: 2582–92.
22. De Donato M, Mariani M, Petrella L, et al. Class III beta-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer. J Cell Physiol 2012; 227: 1034–41.
23. Su D, Smith S, Preti M, et al. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer 2009; 115: 2453–63.
24. Hwang J, Hong J, Kim K, et al. Class III beta- tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer. BMC Cancer 2013; 13: 431.
25. Hasegawa S, Miyoshi Y, Egawa C, et al. Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers. Clin Cancer Res 2003; 9: 2992–7.
26. Paradiso A, Mangia A, Chiriatti A, et al. Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol Suppl 2005; 4: iv14-9.
27. Levallet G, Bergot E, Antoine M, et al. Intergroupe Francophone de Cancérologie Thoracique (IFCT): High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway. Mol Cancer Ther 2012; 11: 1203–13.
28. Seve P, Isaac S, Tredan O, et al. Expression of class III beta-tubulin is predictive of patient outcome in patients with non- small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 2005; 11: 5481–6.
29. Köhne CH. Current stages of adjuvant treatment of colon cancer. Ann Oncol 2012; 23: x71–6.
30. Longley D, Harkin D, Johnston P. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330–8.
31. Peters G, Backus H, Freemantle S, et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 2002; 1587: 194–205.
32. Valastyan S, Weinberg R. Tumor metastasis: Molecular insights and evolving paradigms. Cell 2011; 147: 275–92.
33. Uchibori K, Kasamatsu A, Sunaga M, et al. Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines. Int J Oncol 2012; 40: 1005–10.
34. Littl M, Ludueña R. Structural differences between b1- and b­2-tubulins: implications for microtubule assembly and colchicine binding. EMBO J 1985; 4: 51–6.
35. Bai R, Lin C, Nguyen N, et al. Identification of the cysteine residue of beta-tubulin affected by the antimitotic agent 2,4-dichlorobenzyl thiocyanate, facilitated by separation of the protein subunits of tubulin by hydrophobic column chromatography. Biochemistry 1989; 28: 5606–12.
36. Punnonen K, Ahotupa M, Asaishi K, et al. Antioxidant activities and oxidative stress in human breast cancer. J Cancer Res Clin Oncol 1994; 120: 374–7.
37. Schiff R, Reddy P, Ahotupa M, et al. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst 2000; 92: 1926–34.
38. Portakal O, Ozkaya O, Erden I, et al. Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients. Clin Biochem 2000; 33: 279–84.
39. Ray G, Batra S, Shukla N, et al. Lipid peroxidation, free radical production and antioxidant status in breast cancer. Breast Cancer Res Treat 2000; 59: 163–70.
40. Gilkes D, Semenza G. Role of hypoxia-inducible factors in breast cancer metastasis. Future Oncol 2013; 9: 1623–36.
41. Landino L, Hasan R, McGaw A, et al. Peroxynitrite oxidation of tubulin sulfhydryls inhibits microtubule polymerization. Arch Biochem Biophys 2002: 398: 213–20.
42. Landino L, Skreslet T, Alston J. Cysteine oxidation of tau and microtubule-associated protein-2 by peroxynitrite: modulation of microtubule assembly kinetics by the thioredoxin reductase system. J Biol Chem 2004; 279: 35101–5.
43. Clark H, Hagedorn T, Landino L. Hypothiocyanous acid oxidation of tubulin cysteines inhibits microtubule polymerization. Arch Bioch Bioph 2014; 541: 67–73.
44. Joe P, Banerjee A, Luduena R. The roles of cys124 and ser239 in the functional properties of human beta III tubulin. Cell Motil Cytoskeleton 2008; 65: 476–86.
45. Khan I, Luduena R. Phosphorylation of βIII-tubulin. Biochemistry 1996; 35: 3704–11.
46. Tsourlakis M, Weigand P, Grupp K, et al. βIII-Tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion. Am J Pathol 2014; 184: 609–18.
47. McCarroll J, Gan P, Erlich R, et al. TUBB3/βIII-tubulin acts through the PTEN/AKT signaling axis to promote tumorigenesis and anoikis resistance in non-small cell lung cancer. Cancer Res 2015; 75: 415–25.
48. Dumontet C, Jordan M. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010; 9: 790–803.
49. Katsetos C, Reginato M, Baas P, et al. Emerging microtubule targets in glioma therapy. Semin Pediatr Neurol 2015; 22: 49–72.
50. Nepali K, Ojha R, Lee H, et al. Early investigational tubulin inhibitors as novel cancer therapeutics. Expert Opin Investig Drugs 2016; 8: 917–36.
51. Shibazaki M, Maesawa C, Akasaka K, et al. Transcriptional and post-transcriptional regulation of βIII-tubulin protein expression in relation with cell cycle-dependent regulation of tumor cells. Int J Oncol 2012; 40: 695–702.
52. Parker A, Turner N, McCarroll J, et al. Beta III tubulin alters glucose metabolism and stress response signaling to promote cell survival and proliferation in glucose-starved non-small cell lung cancer cells. Carcinogenesis 2016; 37: 787–98.
53. Panda D, Miller H, Banerjee A, et al. Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc Nat Acad Sci USA 1994; 91: 11358–62.
54. Jensen-Smith H, Eley J, Steyger P, et al. Cell type-specific reduction of beta tubulin isotypes synthesized in the developing gerbil organ of Corti. J Neurocytol 2003; 32: 185–97.
55. Dráberová E, Del Valle L, Gordon J, et al. Class III β-tubulin is constitutively coexpressed with glial fibrillary acidic protein and nestin in midgestational human fetal astrocytes: implications for phenotypic identity. J Neuropathol Exp Neurol 2008; 67: 341–54.
56. Katsetos C, Draber P, Kavallaris M. Targeting βIII-tubulin in glioblastoma multiforme: from cell biology and histopathology to cancer therapeutics. Anticancer Agents Med Chem 2011; 11: 719–28.
57. Foudah D, Monfrini M, Donzelli E, et al. Expression of neural markers by undifferentiated mesenchymal-like stem cells from different sources. J Immunol Res 2014; 2014: 987678–94.


С. Акалович1, А. Портянко2, 3, А. Пундік1, А. Межеєвський4, Т. Дорошенко1, 3*

1Республіканський науково-виробничий центр трансфузіології та медичних біотехнологій, Мінськ 220053, Білорусь
2Білоруський державний медичний університет, Мінськ 220116, Білорусь
3Національний центр раку Білорусі ім. Н.Н. Александрова, Мінськ 223040, Білорусь
4Каролінський інститут, Стокгольм SE-171 76, Швеція

Резюме. Стан питання: Підвищені рівні βIII-тубуліну пов’язані зі стійкістю до широкого спектру ліків та асоціюються з поганим прогнозом при різних типах епітеліального раку. 5-фторурацил (5-ФУ) — стандартний препарат, що широко використовується в хіміотерапевтичних схемах лікування хворих на колоректальний рак, однак стійкість до 5-ФУ є основною перешкодою для успішної терапії. Мета: Метою дослідження було порівняння інвазивних і адгезивних властивостей і рівнів експресії βIII-тубуліну в клітинній лінії HCT116, стійкій до 5-ФУ, та вихідних клітинах HCT116. Матеріали і методи: Лінія клітин HCT116, стійких до 5-ФУ, була отримана шляхом безперервного покрокового відбору зі зростаючими концентраціями 5-ФУ. Життєздатність клітин оцінювали за допомогою МТТ-тесту, визначали адгезивні властивості та оцінювали інвазію в лунках із вставками Transwell. Експресію βIII-тубуліну виявляли методами імуноблотингу та імунофлюоресценції. Результати: Похідна лінія була у 25 разів більш стійка до 5-ФУ і характеризувалася зміненою морфологією клітин. Удвічі більше клітин 5-ФУ-стійкої лінії не проявляли адгезії порівняно з вихідною клітинною лінією. 5-ФУ-стійкі клітини характеризувалися посиленою інвазивністю, що супроводжувалася підвищеною експресією βIII-тубуліну. Крім того, ми виявили, що втрата експресії βIII-тубуліну корелювала з втратою резистентності до 5-ФУ. Висновок: Наші результати свідчать, що навіть незважаючи на те, що дія 5-ФУ не спрямована на мікротрубочки, імовірно, існує кореляція між експресією­ βIII-тубуліну і резистентністю до 5-ФУ, і що це особливо важливо по відношенню до інвазивності. Ці дані вказують на можливий внесок βIII-тубуліну в стійкість до 5-ФУ in vivo.

Ключові слова: колоректальний рак, 5-фторурацил, резистентність до хіміопрепаратів, βIII-тубулін, інвазивність.

No Comments » Add comments
Leave a comment

ERROR: si-captcha.php plugin says GD image support not detected in PHP!

Contact your web host and ask them why GD image support is not enabled for PHP.

ERROR: si-captcha.php plugin says imagepng function not detected in PHP!

Contact your web host and ask them why imagepng function is not enabled for PHP.